Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 638470, 7 pages
http://dx.doi.org/10.1155/2015/638470
Review Article

Th17 Cells in Type 1 Diabetes: Role in the Pathogenesis and Regulation by Gut Microbiome

1Department of Endocrinology, The Second Hospital of Jilin University, Changchun, Jilin 130041, China
2Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University and VA Portland Health Care System, Portland, OR 97239, USA

Received 25 September 2015; Accepted 16 December 2015

Academic Editor: Marije I. Koenders

Copyright © 2015 Yangyang Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Park, Z. Li, X. O. Yang et al., “A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17,” Nature Immunology, vol. 6, no. 11, pp. 1133–1141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. L. E. Harrington, R. D. Hatton, P. R. Mangan et al., “Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages,” Nature Immunology, vol. 6, no. 11, pp. 1123–1132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. L. Gaffen, R. Jain, A. V. Garg, and D. J. Cua, “The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing,” Nature Reviews Immunology, vol. 14, no. 9, pp. 585–600, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Shao, F. He, Y. Yang, G. Yuan, M. Zhang, and X. Yu, “Th17 cells in type 1 diabetes,” Cellular Immunology, vol. 280, no. 1, pp. 16–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Cua, J. Sherlock, Y. Chen et al., “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” Nature, vol. 421, no. 6924, pp. 744–748, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. C. A. Murphy, C. L. Langrish, Y. Chen et al., “Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation,” The Journal of Experimental Medicine, vol. 198, no. 12, pp. 1951–1957, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Lee, A. Awasthi, N. Yosef et al., “Induction and molecular signature of pathogenic TH 17 cells,” Nature Immunology, vol. 13, no. 10, pp. 991–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. I. I. Ivanov, B. S. McKenzie, L. Zhou et al., “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Yosef, A. K. Shalek, J. T. Gaublomme et al., “Dynamic regulatory network controlling TH17 cell differentiation,” Nature, vol. 496, no. 7446, pp. 461–468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. I. I. Ivanov, L. Zhou, and D. R. Littman, “Transcriptional regulation of Th17 cell differentiation,” Seminars in Immunology, vol. 19, no. 6, pp. 409–417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. X. O. Yang, S. H. Chang, H. Park et al., “Regulation of inflammatory responses by IL-17F,” The Journal of Experimental Medicine, vol. 205, no. 5, pp. 1063–1075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Gu, L. Wu, and X. Li, “IL-17 family: cytokines, receptors and signaling,” Cytokine, vol. 64, no. 2, pp. 477–485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Martin-Orozco, Y. Chung, S. H. Chang, Y.-H. Wang, and C. Dong, “Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells,” European Journal of Immunology, vol. 39, no. 1, pp. 216–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Jain, D. M. Tartar, R. K. Gregg et al., “Innocuous IFNγ induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production,” The Journal of Experimental Medicine, vol. 205, no. 1, pp. 207–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Emamaullee, J. Davis, S. Merani et al., “Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice,” Diabetes, vol. 58, no. 6, pp. 1302–1311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Kuriya, T. Uchida, S. Akazawa et al., “Double deficiency in IL-17 and IFN-γ signalling significantly suppresses the development of diabetes in the NOD mouse,” Diabetologia, vol. 56, no. 8, pp. 1773–1780, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. E. P. K. Mensah-Brown, A. Shahin, M. Al-Shamisi, X. Wei, and M. L. Lukic, “IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin,” European Journal of Immunology, vol. 36, no. 1, pp. 216–223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Tong, W. Liu, H. Yan, and C. Dong, “Interleukin-17A deficiency ameliorates streptozotocin-induced diabetes,” Immunology, vol. 146, no. 2, pp. 339–346, 2015. View at Publisher · View at Google Scholar
  20. D. Bending, H. De La Peña, M. Veldhoen et al., “Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice,” The Journal of Clinical Investigation, vol. 119, no. 3, pp. 565–572, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-R. Li, E. E. Mueller, and L. M. Bradley, “Islet antigen-specific Th17 cells can induce TNF-α-dependent autoimmune diabetes,” Journal of Immunology, vol. 192, no. 4, pp. 1425–1432, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Honkanen, J. K. Nieminen, R. Gao et al., “IL-17 immunity in human type 1 diabetes,” Journal of Immunology, vol. 185, no. 3, pp. 1959–1967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. K. Marwaha, S. Q. Crome, C. Panagiotopoulos et al., “Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes,” Journal of Immunology, vol. 185, no. 7, pp. 3814–3818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Arif, F. Moore, K. Marks et al., “Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death,” Diabetes, vol. 60, no. 8, pp. 2112–2119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. E. M. Bradshaw, K. Raddassi, W. Elyaman et al., “Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells,” Journal of Immunology, vol. 183, no. 7, pp. 4432–4439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Ferraro, C. Socci, A. Stabilini et al., “Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes,” Diabetes, vol. 60, no. 11, pp. 2903–2913, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Reinert-Hartwall, J. Honkanen, H. M. Salo et al., “Th1/Th17 plasticity is a marker of advanced β cell autoimmunity and impaired glucose tolerance in humans,” Journal of Immunology, vol. 194, no. 1, pp. 68–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Ryba-Stanisławowska, M. Skrzypkowska, J. Myśliwska, and M. Myśliwiec, “The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes,” Mediators of Inflammation, vol. 2013, Article ID 205284, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Ryba-Stanisławowska, M. Skrzypkowska, M. MyŚliwiec, and J. MyŚliwska, “Loss of the balance between CD4+Foxp3+ regulatory T cells and CD4+IL17A+ Th17 cells in patients with type 1 diabetes,” Human Immunology, vol. 74, no. 6, pp. 701–707, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Kukreja, G. Cost, J. Marker et al., “Multiple immuno-regulatory defects in type-1 diabetes,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 131–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Alonso, M. J. Martínez-Arconada, M. L. Granada et al., “Regulatory T cells in type 1 diabetic patients with autoimmune chronic atrophic gastritis,” Endocrine, vol. 35, no. 3, pp. 420–428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Brusko, C. Wasserfall, K. McGrail et al., “No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes,” Diabetes, vol. 56, no. 3, pp. 604–612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Lindley, C. M. Dayan, A. Bishop, B. O. Roep, M. Peatman, and T. I. M. Tree, “Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes,” Diabetes, vol. 54, no. 1, pp. 92–99, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. L. Putnam, T. M. Brusko, M. R. Lee et al., “Expansion of human regulatory T-cells from patients with type 1 diabetes,” Diabetes, vol. 58, no. 3, pp. 652–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Chaudhry, D. Rudra, P. Treuting et al., “CD4+ regulatory T cells control TH17 responses in a stat3-dependent manner,” Science, vol. 326, no. 5955, pp. 986–991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Ichiyama, H. Yoshida, Y. Wakabayashi et al., “Foxp3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt,” The Journal of Biological Chemistry, vol. 283, no. 25, pp. 17003–17008, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Gaboriau-Routhiau, S. Rakotobe, E. Lécuyer et al., “The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses,” Immunity, vol. 31, no. 4, pp. 677–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. L. V. Hooper, D. R. Littman, and A. J. Macpherson, “Interactions between the microbiota and the immune system,” Science, vol. 336, no. 6086, pp. 1268–1273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Nikoopour and B. Singh, “Reciprocity in microbiome and immune system interactions and its implications in disease and health,” Inflammation and Allergy—Drug Targets, vol. 13, no. 2, pp. 94–104, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. R. E. Ley, D. A. Peterson, and J. I. Gordon, “Ecological and evolutionary forces shaping microbial diversity in the human intestine,” Cell, vol. 124, no. 4, pp. 837–848, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. O. Vaarala, M. A. Atkinson, and J. Neu, “The ‘perfect storm’ for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity,” Diabetes, vol. 57, no. 10, pp. 2555–2562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Alam, E. Bittoun, D. Bhagwat et al., “Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice,” Diabetologia, vol. 54, no. 6, pp. 1398–1406, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Brugman, F. A. Klatter, J. T. J. Visser et al., “Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes?” Diabetologia, vol. 49, no. 9, pp. 2105–2108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. J. L. Dunne, E. W. Triplett, D. Gevers et al., “The intestinal microbiome in type 1 diabetes,” Clinical and Experimental Immunology, vol. 177, no. 1, pp. 30–37, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Wen, R. E. Ley, P. Y. Volchkov et al., “Innate immunity and intestinal microbiota in the development of Type 1 diabetes,” Nature, vol. 455, no. 7216, pp. 1109–1113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. L. F. Roesch, G. L. Lorca, G. Casella et al., “Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model,” ISME Journal, vol. 3, no. 5, pp. 536–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. G. M. Markle, D. N. Frank, S. Mortin-Toth et al., “Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity,” Science, vol. 339, no. 6123, pp. 1084–1088, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Hara, A. K. Alkanani, D. Ir et al., “Prevention of virus-induced type 1 diabetes with antibiotic therapy,” Journal of Immunology, vol. 189, no. 8, pp. 3805–3814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. C. King and N. Sarvetnick, “The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions,” PLoS ONE, vol. 6, no. 2, Article ID e17049, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Ivanov, R. D. L. Frutos, N. Manel et al., “Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine,” Cell Host & Microbe, vol. 4, no. 4, pp. 337–349, 2008. View at Publisher · View at Google Scholar
  51. I. I. Ivanov, K. Atarashi, N. Manel et al., “Induction of intestinal Th17 cells by segmented filamentous bacteria,” Cell, vol. 139, no. 3, pp. 485–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Arpaia, C. Campbell, X. Fan et al., “Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation,” Nature, vol. 504, no. 7480, pp. 451–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. P. M. Smith, M. R. Howitt, N. Panikov et al., “The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis,” Science, vol. 341, no. 6145, pp. 569–573, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Furusawa, Y. Obata, S. Fukuda et al., “Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells,” Nature, vol. 504, no. 7480, pp. 446–450, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Candon, A. Perez-Arroyo, C. Marquet et al., “Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes,” PLOS ONE, vol. 10, no. 5, Article ID e0125448, 2015. View at Publisher · View at Google Scholar
  56. K. Lau, P. Benitez, A. Ardissone et al., “Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias,” The Journal of Immunology, vol. 186, no. 6, pp. 3538–3546, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. M. A. Kriegel, E. Sefik, J. A. Hill, H.-J. Wu, C. Benoist, and D. Mathis, “Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 28, pp. 11548–11553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Valladares, D. Sankar, N. Li et al., “Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats,” PLoS ONE, vol. 5, no. 5, Article ID e10507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. D. M. Tartar, A. M. VanMorlan, X. Wan et al., “FoxP3+RORγt+ T helper intermediates display suppressive function against autoimmune diabetes,” The Journal of Immunology, vol. 184, no. 7, pp. 3377–3385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. S. M. Bellemore, E. Nikoopour, J. A. Schwartz, O. Krougly, E. Lee-Chan, and B. Singh, “Preventative role of interleukin-17 producing regulatory T helper type 17 (T 17) cells in type 1 diabetes in non-obese diabetic mice,” Clinical and Experimental Immunology, vol. 182, no. 3, pp. 261–269, 2015. View at Publisher · View at Google Scholar
  61. E. Gulden, F. S. Wong, and L. Wen, “The gut microbiota and type 1 diabetes,” Clinical Immunology, vol. 159, no. 2, pp. 143–153, 2015. View at Publisher · View at Google Scholar
  62. L. A. Solt, S. Banerjee, S. Campbell, T. M. Kamenecka, and T. P. Burris, “ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes,” Endocrinology, vol. 156, no. 3, pp. 869–881, 2015. View at Publisher · View at Google Scholar
  63. M. Wang, L. Yang, X. Sheng et al., “T-cell vaccination leads to suppression of intrapancreatic Th17 cells through Stat3-mediated RORγt inhibition in autoimmune diabetes,” Cell Research, vol. 21, no. 9, pp. 1358–1369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Wang, J. Hao, D. L. Metzger et al., “Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes,” Diabetes, vol. 60, no. 12, pp. 3246–3255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Bertin-Maghit, D. Pang, B. O'Sullivan et al., “Interleukin-1β produced in response to islet autoantigen presentation differentiates T-helper 17 cells at the expense of regulatory T-cells: implications for the timing of tolerizing immunotherapy,” Diabetes, vol. 60, no. 1, pp. 248–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. K. W. Kalim, M. Basler, C. J. Kirk, and M. Groettrup, “Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation,” The Journal of Immunology, vol. 189, no. 8, pp. 4182–4193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. H.-Y. Qin, M. W. J. Sadelain, C. Hitchon, J. Lauzon, and B. Singh, “Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice,” The Journal of Immunology, vol. 150, no. 5, pp. 2072–2080, 1993. View at Google Scholar · View at Scopus
  68. E. Nikoopour, J. A. Schwartz, K. Huszarik et al., “Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes,” Journal of Immunology, vol. 184, no. 9, pp. 4779–4788, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. X. Gao, G. Ding, Z. Wang et al., “Adjuvant treatment suppresses IL-17 production by T cell-independent myeloid sources in nonobese diabetic mice,” Molecular Immunology, vol. 47, no. 14, pp. 2397–2404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. B. Shi, Z. Wang, H. Jin, Y. W. Chen, Q. Wang, and Y. Qian, “Immunoregulatory Cordyceps sinensis increases regulatory T cells to Th17 cell ratio and delays diabetes in NOD mice,” International Immunopharmacology, vol. 9, no. 5, pp. 582–586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. K. A. Papp, R. G. Langley, M. Lebwohl et al., “Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2),” The Lancet, vol. 371, no. 9625, pp. 1675–1684, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. J.-H. Saurat, G. Stingl, L. Dubertret et al., “Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION),” British Journal of Dermatology, vol. 158, no. 3, pp. 558–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. R. G. Langley, B. E. Elewski, M. Lebwohl et al., “Secukinumab in plaque psoriasis—results of two phase 3 trials,” The New England Journal of Medicine, vol. 371, no. 4, pp. 326–338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Sanford and K. McKeage, “Secukinumab: first global approval,” Drugs, vol. 75, no. 3, pp. 329–338, 2015. View at Publisher · View at Google Scholar · View at Scopus